Study to investigate the relative bioavailability and pharmacokinetics of the fixed-dose combination tablets (telmisartan 40 mg/amlodipine 5 mg and telmisartan 80 mg/amlodipine 5 mg) in the fed condition compared with those of the same fixed-dose combination in the fasting condition in healthy Japanese male volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
32
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)
Time frame: up to 144 hours after drug administration
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: up to 144 hours after drug administration
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: up to 144 hours after drug administration
Time from dosing to the maximum concentration of the analyte in plasma (tmax)
Time frame: up to 144 hours after drug administration
Terminal rate constant of the analyte in plasma (λz)
Time frame: up to 144 hours after drug administration
Terminal half-life of the analyte in plasma (t1/2)
Time frame: up to 144 hours after drug administration
Mean residence time of the analyte in the body after po administration (MRTpo)
Time frame: up to 144 hours after drug administration
Number of subjects with adverse events
Time frame: up to 56 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.